Eli Lilly will spend $3 billion expanding a recently acquired manufacturing facility in Wisconsin to provide capacity for injectable products, including its fast-growing obesity and diabetes drugs.

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

We recently published a list of the 12 Best Long-Term Growth Stocks to Buy Now. In this article, we are going to take a look ...

Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing ...

Sarah O’Keeffe recounts her fulfilling career path with Eli Lilly from employee to Senior Vice President, Product Research ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...

On an investment spree with billions of dollars’ worth of projects ongoing globally, Indianapolis-based Eli Lilly and Company chose Kenosha County for its ...

Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for ...

WEST LAFAYETTE, Ind. — Purdue University, in collaboration with Eli Lilly and Company and Merck & Co. Inc., announced Friday (Jan. 17) the launch of the Young Institute Pharmaceutical Manufacturing ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...